Skip to main content

Advertisement

SpringerLink
Log in

Impact of pharmacist’s intervention on reducing cardiovascular risk in obese patients

  • Research Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background Obesity is a risk factor for cardiovascular disease, the leading cause of death. Health education, nutritional follow-up, and life style habits modification are key for cardiovascular risk reduction in obese patients. Objective To measure the impact of pharmacist’s intervention on cardiovascular risk in obese patients. Setting A Spanish community pharmacy. Method Obese patients (BMI ≥ 30) with (group A, n = 30) and without (group B, n = 14) comorbidities were selected. Variables determined in first visit on-site: anthropometric values (weight, height, waist circumference), blood pressure, glycemic (glucose, HbA1c) and lipid parameters (total cholesterol, HDL-c, LDL-c, triglycerides). The PharmaFit Protocol consisted in a 24-month follow-up focusing (i) monthly on adherence to nutritional guidelines and modification of life style habits, and (ii) bi-monthly on anthropometric variables, blood pressure, and biochemical determinations. Feedback was provided to the primary care physician or specialist. Main ouitcome measure Cardiovascular risk estimated by REGICOR score. Results Anthropometric variables significantly decreased in all groups. Plasma glucose levels were significantly reduced in group A without changes in HbA1c. Lipid parameters significantly improved in group A, whereas HDL-c significantly raised in all groups. REGICOR score was significantly reduced in group A female (13.8 ± 1.6 vs. 5.8 ± 1, p < 0.0001) and male (12.7 ± 1.7 vs. 4.4. ± 0.6, p < 0.005) patients, and in group B female patients (3.5 ± 0.7 vs. 1.9 ± 0.4, p < 0.001). Conclusion Community pharmacist intervention, delivered as a 24-month follow-up and combining health and dietary education, has a highly positive impact on the reduction of cardiovascular risk in obese patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. World Health Organization. Global status report on noncommunicable diseases. Geneva: WHO Library [internet]. Available from. http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng.pdf?ua=1 (2014). Accessed 25 Nov 2018.

  2. Encuesta Nacional de Salud de España 2011/12. Tablas [Spanish national health survey 2011/12. Tables]. Madrid, Ministry of Health, Social Services and Equality, National institute of Statistics. Aviable from. http://www.mscbs.gob.es/estadEstudios/estadisticas/encuestaNacional/encuestaNac2011/DeterminantesSalud_DistribucionPorcentual.pdf (2012). Accessed 25 Nov 2018.

  3. Nagai M, Kuriyama S, Kakizaki M, Ohmori-Matsuda K, Sone T, Hozawa A, Kawado M, Hashimoto S, Tsuji I. Impact of obesity, overweight and underweight on life expectancy and lifetime medical expenditures: The Ohsaki Cohort Study. BMJ Open. 2012;2(3):e000940.

    Article  PubMed  PubMed Central  Google Scholar 

  4. The WHO Global Strategy on Diet. Physical activity and health. Geneva: World Health Organization; 2004. ISBN 92 4 159222 2.

  5. 2008–2013 Action plan for the global strategy for the prevention and control of noncommunicable diseases. World Health Organization, Geneva, (2008). ISBN: 9789241597418.

  6. Omboni S, Caserini M. Effectiveness of pharmacist’s intervention in the management of cardiovascular diseases. Open Heart. 2018;5:e000687.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Rotta I, Salgado TM, Silva ML, Correr CJ, Fernández-Limos F. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000–2010). Int J Clin Pharm. 2015;37(65):687–97.

    Article  CAS  PubMed  Google Scholar 

  8. Ifeanyi Chizaro E, Evans M, van Woerden H, Oparah AC. A systematic review of community pharmacists’ interventions in reducing major risk factors for cardiovascular disease. Value Health Reg Issues. 2015;7:9–21.

    Article  Google Scholar 

  9. O’Neal KS, Crosby KM. What is the role of the pharmacist in obesity management? Curr Obes Rep. 2014;3(3):298–306.

    Article  PubMed  Google Scholar 

  10. Naeem S. Role of pharmacists in obesity management. JPPCM. 2017;3(3):191–3.

    Article  Google Scholar 

  11. Department of Health. Pharmacy in England. Building on strengths—delivering the future. London: HM Government; 2008.

  12. Toubro SDI, Hermansen I, Herborg H, Astrup AV. Dietary guidelines on obesity at Danish pharmacies. Results of a 12-week course with a 1-year follow-up. Ugeskr Laeger. 1999;161(38):5308–513.

    CAS  PubMed  Google Scholar 

  13. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: Commonwealth of Australia; 2003.

    Google Scholar 

  14. Malone M, Alger-Mayer SA, Anderson DA. The lifestyle challenge program: a multidisciplinary approach to weight management. Ann Pharmacother. 2005;39(12):2015–20.

    Article  PubMed  Google Scholar 

  15. Ali O. Get to grips with obesity (4) How pharmacists can contribute to obesity management. The Pharm J. Available from. http://www.pharmaceutical-journal.com/learning/learning-article/get-to-grips-with-obesity-4-how-pharmacists-can-contribute-to-obesity-management/10979028.article.

  16. Declaración de la Profesión farmacéutica: Farmacia comunitaria. Consejo General de Colegios de Farmaceúticos, 2018.

  17. Healthy Food Guide of the Spanish Society of Community Nutrition: Aviable from. www.nutricioncomunitaria.org/es/noticia-documento/19. Accessed Feb 2019.

  18. My Pyramid. Aviable from. https://www.cnpp.usda.gov/mypyramid (2005). Accessed Feb 2019.

  19. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS). Eur Heart J. 2011;32(14):1769–818.

    Article  Google Scholar 

  20. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–24.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Marrugat J, Solanas P, D’Agostino R, Sullivan L, Ordovas J, Cordón F, et al. Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol. 2003;56(3):253–61.

    Article  PubMed  Google Scholar 

  22. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;34(28):2159–219.

    Article  Google Scholar 

  23. Um IS, Armour C, Krass I, Gill T, Chaar BB. Weight management in community pharmacy: what do the experts think? Int J Clin Pharm. 2013;35(3):447–54.

    Article  PubMed  Google Scholar 

  24. Harmon M, Pogge E, Boomershine V. Evaluation of a pharmacist-led, 6-month weight loss program in obese patients. J Am Pharm Assoc. 2014;54(3):302–7.

    Article  Google Scholar 

  25. Gardner SF, Skelton DR, Rollins SD, Hastings JK. Community pharmacy data bases to identify patients at high risk for hypercholesterolemia. Pharmacotherapy. 1995;15(3):292–6.

    CAS  PubMed  Google Scholar 

  26. Tsuyuki RT, Johnson JA, Teo KK, Simpson SH, Ackman ML, Biggs RS, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the study of cardiovascular risk intervention by pharmacists (SCRIP). Arch Intern Med. 2002;162(10):1149–55.

    Article  PubMed  Google Scholar 

  27. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171(16):1441–53.

    Article  CAS  PubMed  Google Scholar 

  28. Neto PR, Marusic S, de Lyra Júnior DP, Pilger D, Cruciol-Souza JM, Gaeti WP, et al. Effect of a 36-month pharmaceutical care program on the coronary heart disease risk in elderly diabetic and hypertensive patients. J Pharm Pharm Sci. 2011;14(2):249–63.

    Article  PubMed  Google Scholar 

  29. Domingues EA, Ferrit-Martín M, Calleja-Hernández MÁ. Impact of pharmaceutical care on cardiovascular risk among older HIV patients on antiretroviral therapy. Int J Clin Pharm. 2017;39(1):52–60.

    Article  CAS  PubMed  Google Scholar 

  30. Taveira TH, Wu WC, Martin OJ, Schleinitz MD, Friedmann P, Sharma SC. Pharmacist-led cardiac risk reduction model. Prev Cardiol. 2006;9(4):202–8.

    Article  PubMed  Google Scholar 

Download references

Funding

This study was funded by GR921645-Santander, Society for the Study of Cardiometabolic Health (SESCAMET).

Author information

Authors and Affiliations

  1. Instituto Pluridisciplinar UCM and Departamento de Farmacología, Farmacognosia y Botánica, Facultad de Farmacia, Universidad Complutense, Madrid, Spain

    Leonor Huete, Francisco Javier Manzano-Lista & Maria S. Fernández-Alfonso

  2. Departamento de Bioquímica, Facultad de Farmacia, Universidad Complutense, Madrid, Spain

    Isabel Aránguez

Authors
  1. Leonor Huete
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco Javier Manzano-Lista
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabel Aránguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria S. Fernández-Alfonso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria S. Fernández-Alfonso.

Ethics declarations

Conflicts of interest

Leonor Huete, Francisco Javier Manzano-Lista, Isabel Aranguez and Maria S. Fernández-Alfonso declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huete, L., Manzano-Lista, F.J., Aránguez, I. et al. Impact of pharmacist’s intervention on reducing cardiovascular risk in obese patients. Int J Clin Pharm 41, 1099–1109 (2019). https://doi.org/10.1007/s11096-019-00856-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-019-00856-w

Keywords

Search

Navigation